Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec 12;4(12):e964.
doi: 10.1038/cddis.2013.506.

TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists

M V Blagosklonny  1
Affiliations
Review

TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists

M V Blagosklonny. Cell Death Dis. .

Abstract

This article is addressed to endocrinologists treating patients with diabetic complications as well as to basic scientists studying an elusive link between diseases and aging. It answers some challenging questions. What is the link between insulin resistance (IR), cellular aging and diseases? Why complications such as retinopathy may paradoxically precede the onset of type II diabetes. Why intensive insulin therapy may initially worsen retinopathy. How nutrient- and insulin-sensing mammalian target of rapamycin (mTOR) pathway can drive insulin resistance and diabetic complications. And how rapamycin, at rational doses and schedules, may prevent IR, retinopathy, nephropathy and beta-cell failure, without causing side effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
mTOR and IR (via a feedback loop) in fat/muscle/liver cells. Insulin via insulin receptor substrate 1/2 (IRS1/2) activates the PI3K/Akt/mTOR/S6K pathway. The mTOR/S6K pathway is also activated by nutrients such as glucose, TNF and numerous other factors. The mTOR/S6K pathway in turn inactivates IRS1/2, thus causing IR
Figure 2
Figure 2
mTOR and retinopathy. See text for explanation
Figure 3
Figure 3
Pre-treatment with rapamycin may prevent negative effects of insulin therapy. (a) Insulin stimulates glucose uptake and metabolism. Simultaneously, insulin activates the mTOR/S6K pathway, causing induction of HIF-1, IR and cell senescence. (b) Acute treatment with rapamycin is expected to prevent negative side effects of insulin, while sparing most effects on glucose metabolism. Short-term courses of rapamycin are expected to restore insulin sensitivity
Figure 4
Figure 4
Consequences of sustained mTOR activation. In the liver, muscle and fat tissues, sustained mTOR activation causes systemic IR. In the beta cells, mTOR initially increases beta-cell function, causes beta-cell hypertrophy and adaptation to IR. Beta-cell hyperfunction and IR eventually may cause beta-cell failure and type II diabetes. In the retina and the kidney, hyperactivation of mTOR may lead to retinopathy and nephropathy, respectively
See this image and copyright information in PMC

References

    1. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest. 2006;116:1756–1760. - PMC - PubMed
    1. Girach A, Vignati L. Diabetic microvascular complications--can the presence of one predict the development of another. J Diabetes Complications. 2006;20:228–237. - PubMed
    1. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7yr before clinical diagnosis. Diabetes Care. 1992;15:815–819. - PubMed
    1. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011;34:145–150. - PMC - PubMed
    1. Ellis JD, Zvandasara T, Leese G, McAlpine R, Macewen CJ, Baines PS, et al. Clues to duration of undiagnosed disease from retinopathy and maculopathy at diagnosis in type 2 diabetes: a cross-sectional study. Br J Ophthalmol. 2011;95:1229–1233. - PubMed

Substances